Recent Advancements in Treatment will help Glioblastoma Treatment Drugs Market to Reach US$ 1.26 Bn at a CAGR of 5.7% Between Forecast Period of 2022-32 | Report by Future Market Insights, Inc.
07 nov. 2022 10h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The global glioblastoma treatment drugs market is worth US$ 723.3 Mn as of now and is expected to reach US$ 1.26 Bn by the year 2032 at a CAGR of 5.7%...
Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada
26 oct. 2022 08h30 HE
|
Brain Cancer Canada
TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
19 oct. 2022 08h00 HE
|
ITM Isotope Technologies Munich SE
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patients Garching/Munich, Germany, October 19, 2022 – ITM...
TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
18 oct. 2022 10h07 HE
|
TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
10 sept. 2022 12h30 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 10, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced today initial results from a Phase 0 clinical trial of pamiparib in...
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
07 sept. 2022 09h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA)
06 sept. 2022 07h59 HE
|
Ocean Biomedical, Inc.
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”....
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
06 sept. 2022 07h45 HE
|
Aesther Healthcare Acquisition Corp.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol,...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26 juil. 2022 07h30 HE
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
Ivy Brain Tumor Center at Barrow Neurological Institute Launches Spanish-Language Website
15 juin 2022 09h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, June 15, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit early-phase drug development program for brain cancer, has announced the...